Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NACDS names top chef

Executive Summary

Following an eight-month search, the National Association of Chain Drug Stores names Steven Anderson CEO Jan. 24. Anderson, who previously headed the National Restaurant Association, takes over for interim CEO Robert Hannan. Hannan assumed the leadership position for a second time following the departure of Craig Fuller in April (1"The Pink Sheet" April 3, 2006, In Brief)...

You may also be interested in...



NACDS names interim chief

Robert Hannan, former interim CEO of the National Association of Chain Drug Stores from April-October 1999, will resume that role effective April 3. Outgoing CEO Craig Fuller will resign effective April 7; Fuller's second in command, COO William Sittmann, will also depart effective immediately. A candidate selection committee will be appointed by association Chairman Anthony Civello after May 1. NACDS says it could take up to one year to find a permanent CEO. [Editor's note: "The Pink Sheet" DAILY broke news of Fuller's departure on March 14]...

After EUA, US Will Ship Only Half Of Doses For Pfizer, Moderna COVID-19 Vaccines

Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.

Medicare Walks Back Proposed Payment Policy For 505(b)(2) Physician Administered Drugs

CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to consider the issue.

UsernamePublicRestriction

Register

SC143406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel